20 This led to a phase II randomized trial with guadecitabine plus carboplatin compared to physician choice that showed a nonsignificant trend for improvement in overall PFS (16.3 weeks vs. 9.1 weeks). 21 However, the 6‐month PFS was significantly higher in the guadecitabine plus carboplatin group (37% vs. 11%, p = 0.003), validating the potential utility of HMAs as re‐sensitization agents. 21 A phase I study also demonstrated early promising results for the use of guadecitabine plus irinotecan in metastatic colon cancer. 42 The MTD of our trial was determined to be 30 mg/m 2 guadecitabine day 1 through day 5 and 100 mg/m 2 cisplatin on day 8 of a 28‐day cycle.
← all excerpts
A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer.
1
—
—